Q1 Earnings Forecast for MLTX Issued By Leerink Partnrs

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of MoonLake Immunotherapeutics in a report issued on Thursday, February 27th. Leerink Partnrs analyst T. Smith expects that the company will earn ($0.82) per share for the quarter. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for MoonLake Immunotherapeutics’ FY2025 earnings at ($3.23) EPS, FY2026 earnings at ($4.30) EPS, FY2027 earnings at ($4.98) EPS and FY2028 earnings at $1.41 EPS.

A number of other equities research analysts also recently weighed in on MLTX. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 target price on shares of MoonLake Immunotherapeutics in a research note on Thursday, February 27th. Needham & Company LLC raised their price target on MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. Wedbush reiterated an “outperform” rating and issued a $73.00 price objective (down from $92.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, November 5th. Finally, The Goldman Sachs Group reduced their price objective on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $83.20.

MoonLake Immunotherapeutics Stock Performance

MoonLake Immunotherapeutics stock opened at $40.30 on Monday. The stock has a market cap of $2.58 billion, a P/E ratio of -31.24 and a beta of 1.28. MoonLake Immunotherapeutics has a fifty-two week low of $37.55 and a fifty-two week high of $58.26. The firm’s fifty day moving average price is $46.24 and its 200-day moving average price is $48.89.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.09).

Institutional Investors Weigh In On MoonLake Immunotherapeutics

A number of large investors have recently added to or reduced their stakes in the company. FMR LLC grew its stake in shares of MoonLake Immunotherapeutics by 28.1% in the fourth quarter. FMR LLC now owns 6,341,391 shares of the company’s stock worth $343,386,000 after purchasing an additional 1,391,167 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in MoonLake Immunotherapeutics by 12.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,343,643 shares of the company’s stock valued at $181,059,000 after acquiring an additional 363,394 shares in the last quarter. Paradigm Biocapital Advisors LP increased its position in MoonLake Immunotherapeutics by 90.3% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,772,211 shares of the company’s stock valued at $95,965,000 after purchasing an additional 840,731 shares during the period. Federated Hermes Inc. lifted its position in shares of MoonLake Immunotherapeutics by 13.2% in the 4th quarter. Federated Hermes Inc. now owns 1,280,052 shares of the company’s stock worth $69,315,000 after purchasing an additional 149,724 shares during the period. Finally, Marshall Wace LLP boosted its stake in shares of MoonLake Immunotherapeutics by 7.9% during the 4th quarter. Marshall Wace LLP now owns 1,245,299 shares of the company’s stock valued at $67,433,000 after purchasing an additional 90,914 shares in the last quarter. Institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.